English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/204684
logo share SHARE   Add this article to your Mendeley library MendeleyBASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:


Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015)

AuthorsPalomo, Valle ; Martínez, Ana
KeywordsAlzheimer’s disease
GSK-3 inhibitors
Stem cells
Regenerative medicine
Issue Date21-Nov-2016
PublisherTaylor & Francis
CitationExpert opinion on therapeutic patents 27(6) 657-666 (2016)
AbstractIntroduction: Glycogen synthase kinase (GSK-3) is a serine/threonine kinase that phosphorylates more than one hundred different sequences within proteins in a variety of different pathways. It is a key component of a remarkably large number of cellular processes and diseases. Imbalance of GSK-3 activity is involved in various prevalent pathological diseases, such as diabetes, neurodegenerative diseases and cancer.Understanding its role in different disorders has been central in the last several decades and there has been a significantly large development of GSK-3 inhibitors, some of which, show promising results for the treatment of these devastating diseases.Areas covered: This review covers patent literature on GSK-3 inhibitors and their applications published and/or granted between 2014 and 2015.Expert opinion: GSK-3 inhibitors have gained a prominent role in regenerative medicine based in their ability to modulate stem cells. Moreover, some allosteric modulators of GSK-3 emerge as safe compounds for chronic treatments.
Description30 p.-5 fig.
Publisher version (URL)https://doi.org/10.1080/13543776.2017.1259412
Appears in Collections:(CIB) Artículos
Files in This Item:
File Description SizeFormat 
Expert Opinion on Therapeutic Patents_palomo_2016.pdfPostprint653,63 kBAdobe PDFThumbnail
Show full item record
Review this work

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.